Voyager Therapeutics

Voyager Therapeutics

Edit info

  • Founded: 2014
  • Location: Cambridge, MA
  • Employee range: 200 - 500
  • Clinical stage: RD
  • Therapy area: Alzheimer's
  • Drug types: NEU, RAR
  • Lead product: Undisclosed
  • Funding: $60M B Apr 2015


voyagertherapeutics.com

linkedin.com

job board


Business:

AAV capsid Gene Therapy

Drug notes:

13+ additional undisclosed programs RD ALS, Friedreich's ataxia, Parkinson's, rare neurological disease, CNS diseases, undisclosed

About:

Voyager Therapeutics is advancing delivery modalities for gene therapies. Many gene therapies are in development, yet delivery of the therapy is still a major limitation. AAVs are a popular choice but require high doses and have off-target effects. Voyager is using its TRACER screening platform to enhance AAV capsids’ specificity and ability to target desired cells and tissues. Voyager’s AAVs also pass the blood-brain barrier, offering the potential to cure neurological diseases. Initial non-human primate data demonstrate the selectivity of TRACER-derived capsids to target the CNS and cardiac muscle. These capsids may enable single-dose treatment for a broad spectrum of diseases.

Voyager Therapeutics
Director/Senior Director, Corporate Counsel
Lexington, MA|10 days ago
Apply
Voyager Therapeutics
Senior Scientist, Oligonucleotide Chemistry
Lexington, MA|16 days ago
Voyager Therapeutics
Senior Scientist, Bioconjugation
Lexington, MA|23 days ago


© 2025 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com